



DLA Piper (Canada) LLP
Suite 6000, 1 First Canadian Place
PO Box 367, 100 King St W
Toronto ON M5X 1E2
www.dlapiper.com

DLA Piper (Canada) LLP

T 416.365.3500

F 416.365.7886

June 4, 2020

080340-00004

VIA SEDAR

Alberta Securities Commission
British Columbia Securities Commission
Financial and Consumer Affairs Authority of Saskatchewan
The Manitoba Securities Commission
Ontario Securities Commission
Nova Scotia Securities Commission
Financial and Consumer Services Commission (New Brunswick)
Office of the Superintendent of Securities (Prince Edward Island)
Office of the Superintendent of Securities Service Newfoundland and Labrador

**Re: Innocan Pharma Corporation (the “Company”)
Final Short Form Prospectus dated June 4, 2020 (the “Prospectus”), filed pursuant to
National Instrument 41-101 *General Prospectus Requirements* and Multilateral Instrument
11-102 *Passport System***

We refer to the Prospectus relating to the public offering of units of the Company. We consent to the use of our name, DLA Piper (Canada) LLP, on page “iii” and under the heading “Legal Matters” in the Prospectus and to the use of our name, DLA Piper (Canada) LLP, and our opinions under the headings “Eligibility for Investment” and “Certain Canadian Federal Income Tax Considerations” in the Prospectus.

We confirm that we have read the Prospectus and have no reason to believe that there are any misrepresentations in the information contained therein that is derived from our opinions referred to above or that is within our knowledge as a result of the services we performed in connection with such opinions.

Sincerely,

(signed) “*DLA Piper (Canada) LLP*”